

# Xavier Kurz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103728/publications.pdf>

Version: 2024-02-01

44  
papers

1,222  
citations

393982

19  
h-index

395343

33  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1903  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 36-39.   | 2.3 | 180       |
| 2  | Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. <i>BMC Medicine</i> , 2018, 16, 6.                         | 2.3 | 87        |
| 3  | EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. <i>Drug Safety</i> , 2018, 41, 665-675.   | 1.4 | 73        |
| 4  | Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 419-433.  | 1.1 | 62        |
| 5  | Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real-World Evidence?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 90-97.   | 2.3 | 58        |
| 6  | Patient Registries: An Underused Resource for Medicines Evaluation. <i>Drug Safety</i> , 2019, 42, 1343-1351.   | 1.4 | 56        |
| 7  | Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. <i>Clinical Drug Investigation</i> , 2019, 39, 205-213.                                   | 1.1 | 51        |
| 8  | Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. <i>JAMA Neurology</i> , 2019, 76, 827.   | 4.5 | 49        |
| 9  | Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2016, 6, e009147.   | 0.8 | 47        |
| 10 | Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. <i>Vaccine</i> , 2012, 30, 7123-7129.  | 1.7 | 46        |
| 11 | Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. <i>BMJ Open</i> , 2018, 8, e023090.   | 0.8 | 40        |
| 12 | Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 156-165.   | 0.9 | 36        |
| 13 | Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 825-831.  | 0.9 | 36        |
| 14 | Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 245-252. | 0.9 | 33        |
| 15 | Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1442-1450.  | 0.9 | 32        |
| 16 | Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1336-1345.                     | 1.1 | 30        |
| 17 | Increasing scientific standards, independence and transparency in post-authorization studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 690-696.      | 0.9 | 27        |
| 18 | Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1034-1051.                      | 1.1 | 26        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. <i>Vaccine</i> , 2011, 29, 4378-4387.   | 1.7 | 22        |
| 20 | Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. <i>Vaccine</i> , 2020, 38, B1-B7.   | 1.7 | 20        |
| 21 | The ADVANCE Code of Conduct for collaborative vaccine studies. <i>Vaccine</i> , 2017, 35, 1844-1855.   | 1.7 | 19        |
| 22 | Barriers and Opportunities for Use of Patient Registries in Medicines Regulation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 39-42.  | 2.3 | 17        |
| 23 | Application of real-time global media monitoring and "derived questions"™ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines. <i>BMC Medicine</i> , 2017, 15, 91.                                 | 2.3 | 15        |
| 24 | Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study. <i>Clinical Drug Investigation</i> , 2018, 38, 927-933.           | 1.1 | 14        |
| 25 | A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1086-1096.                                      | 0.9 | 13        |
| 26 | Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance. <i>Vaccine</i> , 2016, 34, 4892-4897.                             | 1.7 | 12        |
| 27 | Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe. <i>Vaccine</i> , 2019, 37, 3278-3289.   | 1.7 | 12        |
| 28 | Prescribing patterns of tramadol in adults in IMSA® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 707-716.                            | 0.8 | 11        |
| 29 | Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 915-925.                              | 2.3 | 11        |
| 30 | Antiepileptic drugs and risk of suicide attempts: a case-control study exploring the impact of underlying medical conditions. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 239-247.   | 0.9 | 10        |
| 31 | Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 979-984.     | 0.8 | 10        |
| 32 | The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 422-433.                                  | 0.9 | 10        |
| 33 | What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 334-341.                     | 0.9 | 10        |
| 34 | Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1336-1340.                          | 0.9 | 9         |
| 35 | Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 823-826.   | 0.9 | 8         |
| 36 | Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-control Study. <i>Clinical Drug Investigation</i> , 2019, 39, 591-594. | 1.1 | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2011, 11, 304-307.   | 0.6 | 5         |
| 38 | Does additional monitoring status increase the reporting of adverse drug reaction<scp>s</scp>? An interrupted time series analysis of <scp>EudraVigilance</scp> data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 350-359.                             | 0.9 | 5         |
| 39 | Advancing regulatory science, advancing regulatory practice. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 722-726.  | 0.9 | 4         |
| 40 | Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 957-965.   | 2.3 | 3         |
| 41 | Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database. <i>Drug Safety</i> , 0, , .  | 1.4 | 2         |
| 42 | Increasing the impact of Post Authorisation Safety Studies: transparency is key. <i>European Journal of Internal Medicine</i> , 2021, 83, 6-7.   | 1.0 | 1         |
| 43 | International Collaboration in Realâ€World Evidence Generation for Direct Acting Oral Antiâ€Coagulants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 299-301.  | 2.3 | 1         |
| 44 | Authorsâ€™ Reply to Ravi Jandhyalaâ€™s Comment on â€œPatient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessmentsâ€: <i>Drug Safety</i> , 2019, 42, 1517-1518. | 1.4 | 0         |